# A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

> **NCT05926492** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 160 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Surufatinib plus chemotherapy
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05926492
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-09
- **Primary completion:** 2025-07
- **Final completion:** 2026-07
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926492, "A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05926492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*